Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 50,716 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12. Following the transaction, the chief operating officer now directly owns 216,286 shares in the company, valued at $6,828,149.02. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total value of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total value of $281,800.00.
• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $14,870.24.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock opened at $32.74 on Wednesday. Akero Therapeutics, Inc. has a 52 week low of $13.39 and a 52 week high of $37.00. The business’s fifty day simple moving average is $28.54 and its 200-day simple moving average is $24.97. The firm has a market cap of $2.27 billion, a PE ratio of -9.60 and a beta of -0.26. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.09. Equities analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds have recently bought and sold shares of AKRO. Principal Financial Group Inc. lifted its stake in Akero Therapeutics by 15.6% during the 1st quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after acquiring an additional 1,858 shares in the last quarter. Swiss National Bank lifted its stake in Akero Therapeutics by 19.9% during the 1st quarter. Swiss National Bank now owns 105,000 shares of the company’s stock worth $2,652,000 after acquiring an additional 17,400 shares in the last quarter. Headlands Technologies LLC lifted its stake in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after acquiring an additional 3,024 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Finally, ProShare Advisors LLC increased its holdings in Akero Therapeutics by 24.4% during the 1st quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock worth $379,000 after purchasing an additional 2,945 shares during the period.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Akero Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.20.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.